前臨床用画像システム及び試薬の世界市場：光学イメージング装置、核イメージング装置、マイクロMRI、マイクロ超音波、マイクロCT、MPI装置...市場調査レポートについてご紹介

【英文タイトル】Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要（一部）】

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 19
1.3 MARKET SCOPE 19
1.3.1 LIMITATION 19
1.3.2 MARKETS COVERED 19
1.3.3 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH DATA 22
2.1.1 SECONDARY DATA 22
2.1.1.1 Key Data From Secondary Sources 23
2.1.2 PRIMARY DATA 23
2.1.2.1 Breakdown of Primaries 24
2.1.2.2 Key Data From Primary Sources 24
2.1.2.3 Key Industry Insights 25
2.2 MARKET SIZE ESTIMATION 25
2.2.1.1 Bottom-up Approach 25
2.2.1.2 Top-down Approach 26
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.4 RESEARCH ASSUMPTIONS & LIMITATIONS 29
2.4.1 ASSUMPTIONS 29
2.4.2 LIMITATIONS 29

3 EXECUTIVE SUMMARY 30
3.1 INTRODUCTION 30
3.2 CURRENT SCENARIO 31
3.3 FUTURE OUTLOOK 32
3.4 CONCLUSION 34

4 PREMIUM INSIGHTS 35
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE PRECLINICAL IMAGING MARKET 35
4.2 PRECLINICAL IMAGING REAGENTS MARKETS, BY REGION (2014) 36
4.3 GLOBAL PRECLINICAL IMAGING SYSTEMS, BY REGION (2014) 37
4.4 GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET, BY MODALITY, (2014–2019) 38

5 MARKET OVERVIEW 39
5.1 INTRODUCTION 39
5.2 MARKET SEGMENTATION 39
5.2.1 BY MODALITY 40
5.2.2 BY REAGENT 41
5.3 MARKET DYNAMICS 41
5.3.1 DRIVERS 42
5.3.1.1 Advancements in molecular imaging technologies 42
5.3.1.2 Growing acceptance of preclinical imaging as a legitimate drug development tool 43
5.3.1.3 Increasing demand for multi-modality imaging technologies in preclinical research 44
5.3.1.4 Increasing number of preclinical research activities 44
5.3.2 RESTRAINTS 45
5.3.2.1 High implementation costs of imaging systems 45
5.3.2.2 Reduced NIH funding for life science research activities 45
5.3.2.3 High cost and data requirements for developing new imaging technologies 46
5.3.3 OPPORTUNITIES 46
5.3.3.1 Emerging markets offer lucrative growth opportunities for market players 46
5.3.3.2 Major companies exiting from the preclinical imaging market is opening new growth avenues for existing market players 47
5.3.3.3 Integration of preclinical MRI systems with other imaging modalities 48
5.3.3.4 Development of low-cost imaging devices with high resolution and sensitivity 48
5.3.4 CHALLENGES 48
5.3.4.1 Technological limitations of standalone preclinical imaging modalities 48
5.3.4.2 Challenges associated with the application of radioisotopes negatively affects the demand of micro-PET systems 49

6 INDUSTRY INSIGHTS 50
6.1 INTRODUCTION 50
6.2 VALUE CHAIN ANALYSIS 50
6.3 SUPPLY CHAIN ANALYSIS 51
6.3.1 KEY STAKEHOLDERS 52
6.3.2 KEY INFLUENCERS 52
6.4 INDUSTRY TRENDS 53
6.4.1 RISING FOCUS OF MARKET PLAYERS TOWARDS THE DEVELOPMENT OF HYBRID PRECLINICAL IMAGING SYSTEMS 53
6.4.2 INCREASING GOVERNMENT FUNDING FOR PHARMACEUTICAL RESEARCH AND DEVELOPMENT IN EMERGING NATIONS 53
6.5 PORTER’S FIVE FORCES ANALYSIS 54
6.5.1 THREAT FROM NEW ENTRANTS 54
6.5.2 THREAT FROM SUBSTITUTES 55
6.5.3 BARGAINING POWER OF SUPPLIERS 55
6.5.4 BARGAINING POWER OF BUYERS 56
6.5.5 INTENSITY OF COMPETITIVE RIVALRY 56

7 GLOBAL PRECLINICAL IMAGING MARKET, BY MODALITY 57
7.2 INTRODUCTION 58
7.3 OPTICAL IMAGING SYSTEMS 59
7.3.1 BIOLUMINESCENCE/FLUORESCENCE IMAGING SYSTEMS 62
7.3.2 STANDALONE FLUORESCENCE IMAGING SYSTEMS 63
7.3.3 OPTICAL + X-RAY/OPTICAL + CT 65
7.4 PRECLINICAL NUCLEAR IMAGING SYSTEMS 66
7.4.1 MICRO-PET SYSTEMS 69
7.4.1.1 Standalone PET Systems 71
7.4.1.2 PET/CT Systems 71
7.4.1.3 PET/MRI Systems 72
7.4.2 MICRO-SPECT SYSTEMS 73
7.4.2.1 Standalone SPECT Systems 74
7.4.2.2 SPECT/CT Systems 75
7.4.2.3 SPECT/MRI Systems 75
7.4.3 TRIMODALITY (SPECT/PET/CT) SYSTEMS 76
7.5 MICRO-MRI 76
7.6 MICRO-ULTRASOUND 78
7.7 MICRO-CT 79
7.8 PRECLINICAL PHOTOACOUSTIC IMAGING SYSTEMS 81
7.9 PRECLINICAL MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS 82

8 GLOBAL PRECLINICAL IMAGING MARKET, BY REAGENTS 83
8.1 INTRODUCTION 84
8.2 PRECLINICAL OPTICAL IMAGING REAGENTS 85
8.2.1 BIOLUMINESCENT IMAGING REAGENTS 87
8.2.1.1 Luciferins 90
8.2.1.1 Proluciferins 90
8.2.1.2 Coelenterazine 91
8.2.1.3 Others 92
8.2.2 FLUORESCENT IMAGING REAGENTS 92
8.2.2.1 Green Fluorescent Proteins 95
8.2.2.2 Red Fluorescent Proteins 95
8.2.2.3 Infrared Dyes 96
8.2.2.4 Others (Natural fluorescence molecules such as Collagen and Elastin) 97
 
8.3 PRECLINICAL NUCLEAR IMAGING REAGENTS 98
8.3.1 PRECLINICAL PET TRACERS 100
8.3.1.1 Fluorine-18-based Preclinical PET Tracers 101
8.3.1.2 Carbon-11-based Preclinical PET Tracers 102
8.3.1.3 Copper-64-based Preclinical PET Tracers 103
8.3.1.4 Others 103
8.3.2 PRECLINICAL SPECT PROBES 104
8.3.2.1 Technetium-99m-based Preclinical SPECT Probes 106
8.3.2.2 Iodine-131-based Preclinical SPECT Probes 107
8.3.2.3 Gallium-67-based Preclinical SPECT Probes 107
8.3.2.4 Thallium-201-based Preclinical SPECT Probes 108
8.3.2.5 Others 109
8.4 PRECLINICAL MRI CONTRAST AGENTS 109
8.4.1 GADOLINIUM-BASED PRECLINICAL MRI CONTRAST AGENTS 112
8.4.2 IRON-BASED PRECLINICAL MRI CONTRAST AGENTS 112
8.4.3 MANGANESE-BASED PRECLINICAL MRI CONTRAST AGENTS 113
8.5 PRECLINICAL ULTRASOUND CONTRAST AGENTS 114
8.6 PRECLINICAL CT CONTRAST AGENTS 115
8.6.1 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS 117
8.6.2 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS 118
8.6.3 GOLD NANOPARTICLES 118
8.6.4 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS 119

9 GEOGRAPHIC ANALYSIS 120
9.1 INTRODUCTION 121
9.2 NORTH AMERICA 122
9.3 EUROPE 126
9.4 ASIA-PACIFIC 129
9.5 REST OF THE WORLD (ROW) 133

10 COMPETITIVE LANDSCAPE 136
10.1 OVERVIEW 136
10.2 MARKET SHARE ANALYSIS: PRECLINICAL IMAGING MARKET, BY KEY PLAYER, 2013 137
10.3 COMPETITIVE SITUATION AND TRENDS 138
10.3.1 NEW PRODUCT LAUNCHES AND PRODUCT DEVELOPMENTS 139
10.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 140
10.3.3 GEOGRAPHICAL EXPANSIONS 141
10.3.4 MERGERS AND ACQUISITIONS 142
10.3.5 OTHER DEVELOPMENTS 143

11 COMPANY PROFILES 145
11.1 INTRODUCTION 145
11.2 PERKINELMER, INC. 145
11.2.1 BUSINESS OVERVIEW 145
11.2.2 PRODUCT PORTFOLIO 147
11.2.3 KEY STRATEGY 147
11.2.4 KEY DEVELOPMENTS (2012-2014) 148
11.2.5 SWOT ANALYSIS 149
11.3 BRUKER CORPORATION 150
11.3.1 BUSINESS OVERVIEW 150
11.3.2 PRODUCT PORTFOLIO 151
11.3.3 KEY STRATEGY 151
11.3.4 KEY DEVELOPMENTS (2012–2014) 152
11.3.5 SWOT ANALYSIS 153
11.4 FUJIFILM VISUALSONICS, INC. 154
11.4.1 BUSINESS OVERVIEW 154
11.4.2 PRODUCT PORTFOLIO 154
11.4.3 KEY STRATEGY 155
11.4.4 KEY DEVELOPMENTS (2012–2014) 155
11.4.5 SWOT ANALYSIS 156
11.5 MEDISO LTD. 157
11.5.1 BUSINESS OVERVIEW 157
11.5.2 PRODUCT PORTFOLIO 157
11.5.3 KEY STRATEGY 157
11.5.4 KEY DEVELOPMENTS (2012–2014) 158
11.5.5 SWOT ANALYSIS 159
11.6 TRIFOIL IMAGING 160
11.6.1 BUSINESS OVERVIEW 160
11.6.2 PRODUCT PORTFOLIO 160
11.6.3 KEY STRATEGY 161
11.6.4 KEY DEVELOPMENTS (2012–2014) 161
11.7 MR SOLUTIONS LTD. 163
11.7.1 BUSINESS OVERVIEW 163
11.7.2 PRODUCT PORTFOLIO 163
11.7.3 KEY STRATEGY 163
11.7.4 KEY DEVELOPMENTS (2012-2014) 164
11.8 ASPECT IMAGING 165
11.8.1 BUSINESS OVERVIEW 165
11.8.2 PRODUCT PORTFOLIO 165
11.8.3 KEY STRATEGY 165
11.8.4 KEY DEVELOPMENTS (2012–2014) 166
11.9 BIOSPACE LAB S.A. 167
11.9.1 BUSINESS OVERVIEW 167
11.9.2 PRODUCT PORTFOLIO 167
11.9.3 KEY STRATEGY 167
11.9.4 KEY DEVELOPMENTS (2012–2014) 168
11.10 LI-COR BIOSCIENCES 169
11.10.1 BUSINESS OVERVIEW 169
11.10.2 PRODUCT PORTFOLIO 169
11.10.3 KEY STRATEGY 170
11.10.4 KEY DEVELOPMENTS (2012-2014) 170
11.11 MILABS B.V. 172
11.11.1 BUSINESS OVERVIEW 172
11.11.2 PRODUCT PORTFOLIO 172
11.11.3 KEY STRATEGY 173
11.11.4 KEY DEVELOPMENTS (2012–2014) 173

12 APPENDIX 174
12.1 INSIGHTS OF INDUSTRY EXPERTS 174
12.2 DISCUSSION GUIDE* 175
12.3 COMPANY DEVELOPMENTS (2012–2014) 179
12.3.1 ASPECT IMAGING 179
12.3.2 BRUKER CORPORATION 179
12.3.3 LI-COR BIOSCIENCES 180
12.3.4 MEDISO LTD. 182
12.3.5 MILABS B.V. 182
12.3.6 PERKINELMER, INC. 182
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 184
12.5 AVAILABLE CUSTOMIZATIONS 185
12.6 RELATED REPORTS 186

【レポート販売概要】

■ タイトル：前臨床用画像システム及び試薬の世界市場：光学イメージング装置、核イメージング装置、マイクロMRI、マイクロ超音波、マイクロCT、MPI装置
■ 英文：Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging) - Global Forecasts to 2019
■ 発行日：2015年1月30日
■ 調査会社：MarketsandMarkets
■ 商品コード：MAM-MD-3117
■ 調査対象地域：グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業（メーカー、ベンダー）、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。

Follow:

RSS [PRニュース]